D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Lowers Price Target to $6

Benzinga · 06/10 12:06
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and lowers the price target from $9 to $6.